Acadia Pharma (ACAD) Tops Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Acadia Pharmaceuticals Reports First Quarter 2021 Financial Results
May 5, 2021 4:10 PM EDT- 1Q21 net sales of $106.6 million, an 18% increase over 1Q20
- Reiterating FY21 net sales guidance of $510 to $550 million
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2021.
NUPLAZID delivered strong year-over-year performance in the first quarter of 2021. Looking ahead, we see positive signs in the Parkinsons disease psychosis market supporting revenue growth for the remainder of the year as we anticipate continued improvements in the conditions related to the... More
